Skip to main content
. 2015 Mar 15;2015:273489. doi: 10.1155/2015/273489

Figure 1.

Figure 1

Disease-free survival of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/− cetuximab based chemoradiotherapy as preoperative treatment (n = 86). Shown are survival curves of patients treated with CapIri (solid curve; n = 37) versus patients treated with CapIri + cetuximab (dotted curve; n = 49), P = 0.62.